GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daewoong Pharmaceutical Co Ltd (XKRX:069620) » Definitions » Debt-to-Asset

Daewoong Pharmaceutical Co (XKRX:069620) Debt-to-Asset : 0.33 (As of Dec. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Daewoong Pharmaceutical Co Debt-to-Asset?

Daewoong Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩323,497 Mil. Daewoong Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩325,752 Mil. Daewoong Pharmaceutical Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was ₩1,976,977 Mil. Daewoong Pharmaceutical Co's debt to asset for the quarter that ended in Dec. 2024 was 0.33.


Daewoong Pharmaceutical Co Debt-to-Asset Historical Data

The historical data trend for Daewoong Pharmaceutical Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daewoong Pharmaceutical Co Debt-to-Asset Chart

Daewoong Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.33 0.32 0.29 0.25 0.33

Daewoong Pharmaceutical Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 0.26 0.29 0.31 0.33

Competitive Comparison of Daewoong Pharmaceutical Co's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Daewoong Pharmaceutical Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daewoong Pharmaceutical Co's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daewoong Pharmaceutical Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Daewoong Pharmaceutical Co's Debt-to-Asset falls into.



Daewoong Pharmaceutical Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Daewoong Pharmaceutical Co's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(323497.286 + 325751.87) / 1976977.111
=0.33

Daewoong Pharmaceutical Co's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(323497.286 + 325751.87) / 1976977.111
=0.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Daewoong Pharmaceutical Co  (XKRX:069620) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Daewoong Pharmaceutical Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Daewoong Pharmaceutical Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Daewoong Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
12, Bongeunsa-ro 114-gil, Daewoong Pharmaceutical Building, Gangnam-gu, Seoul, KOR
Daewoong Pharmaceutical Co Ltd develops, manufactures and sells prescription drug products. The company's product portfolio comprises products such as Moxicle, Plunazol Cap, Bearcef tab, Newdizime etc. It develops and promotes brands such as Ursa, Nabota, Luphere, Easyef, Cretropin. The company has manufacturing facilities at Hyangnam and Sungnam.

Daewoong Pharmaceutical Co Headlines

No Headlines